News

August 11, 2016August 11, 2016

Peritoneal Mesothelioma Linked to Chronic Inflammation of Crohn’s Disease in Study

News

The vast majority of malignant mesothelioma (MM) cases are caused by asbestos exposure, but reports have suggested that chronic inflammation may also lead to development of this cancer. In a recent ... Read more

August 9, 2016August 9, 2016

New Mesothelioma Therapy Soon to Enter Clinical Trials in Japan

News

A new anti-CD26 monoclonal antibody, YS110, may be a promising therapeutic approach for patients with malignant mesothelioma (MM), according to researchers at the Graduate School of Medicine, Juntendo University, in ... Read more

August 4, 2016August 4, 2016

Elderly Patients with Malignant Pleural Mesothelioma May Benefit from Surgery

News

Surgery improves overall survival in patients with malignant pleural mesothelioma, even among elderly patients, according to the results of the study, “Impact of Age on Long-Term Outcomes of Surgery for Malignant ... Read more

August 2, 2016August 2, 2016

Mesothelioma Cases Rise in Iceland Despite Asbestos Ban

News

According to recent research, mesothelioma continues to rise in Iceland, a country that was once a heavy importer of the mineral asbestos. The study “Malignant mesothelioma incidence by nationwide cancer ... Read more

July 28, 2016July 28, 2016

Two with Mesothelioma Respond to New Therapy Combo Using Lurbinectedin

News

A new mesothelioma treatment based on the marine-derived drug lurbinectedin showed promising results in a preliminary study in two patients who had previously failed to respond to conventional therapy. The study, ... Read more

July 26, 2016July 26, 2016

Positive Preclinical Results Reported in Mesothelioma Model for ONCOS-102

News

Results from a preclinical study using a mesothelioma animal model demonstrate a synergic effect of ONCOS-102, a genetically modified adenovirus, in combination with pemetrexed and cisplatin. “These findings give a strong ... Read more

July 21, 2016July 21, 2016

First Patient Recruited in Malignant Pleural Mesothelioma PhaseIb/II Trial

News

Scandinavian-based Targovax recently recruited the first patient for the Phase Ib/II study examining ONCOS-102 in combination with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma (MPM), a rare, aggressive cancer ... Read more

July 19, 2016July 19, 2016

NCCN Panel Favors New Mesothelioma Drug Combo as First-Line Therapy

News

The National Comprehensive Cancer Network (NCCN), an alliance of 27 major U.S. cancer centers, has expanded its recommendation for first-line pleural mesothelioma treatment to include the monoclonal antibody drug Avastin (bevacizumab) as a combination therapy ... Read more

July 14, 2016July 14, 2016

Specific Inhibitors Can Reduce Mesothelioma Tumor Growth, According to Study

News

Inhibitors of a specific receptor, P2X7, decrease tumor growth in malignant pleural mesothelioma, according to the results of a study titled “P2X7 targeting inhibits growth of human mesothelioma,” published in the journal ... Read more

July 12, 2016July 12, 2016

Water Channel Protein May Help to Diagnose Malignant Mesothelioma

News

Researchers have found that a protein, named Aquaporin 1 (AQP1), is a valuable biomarker in malignant mesothelioma patients. The study, “Usefulness of Aquaporin 1 as a Prognostic Marker in a Prospective ... Read more